Ondine Biomedical, Inc. Statistics
Want to see GB:OBI full AI Analyst Report?
Ondine Biomedical, Inc. (OBI) Stock Statistics & Valuation Metrics
Total Valuation
Ondine Biomedical, Inc. has a market cap or net worth of GBX 58.85M. The enterprise value is GBX 77.17M.
- Market Cap
- GBX 58.85M
- Enterprise Value
- GBX 77.17M
Share Statistics
Ondine Biomedical, Inc. has 661,218,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 661,218,140
- Owned by Insiders
- 26.81%
- Owned by Institutions
- ―
Financial Efficiency
Ondine Biomedical, Inc.’s return on equity (ROE) is -8.48 and return on invested capital (ROIC) is -769.72%.
- Return on Equity (ROE)
- -8.48
- Return on Assets (ROA)
- -2.06
- Return on Invested Capital (ROIC)
- -769.72%
- Return on Capital Employed (ROCE)
- -8.37
- Revenue Per Employee
- 147.36K
- Profits Per Employee
- -1.64M
- Employee Count
- 18
- Asset Turnover
- 0.18
- Inventory Turnover
- 0.86
Valuation Ratios
The current PE Ratio of Ondine Biomedical, Inc. is -2.66. Ondine Biomedical, Inc.’s PEG ratio is -0.03.
- PE Ratio
- -2.66
- PS Ratio
- 39.77
- PB Ratio
- -28.35
- Price to FCF
- -4.23
- Price to Operating Cash Flow
- -3.44
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Ondine Biomedical, Inc. had revenue of 2.65M and earned -29.59M in profits. Earnings per share was -0.06.
- Revenue
- 2.65M
- Gross Profit
- 1.09M
- Operating Income
- -30.04M
- Pretax Income
- -29.59M
- Net Income
- -29.59M
- EBITDA
- -29.45M
- Earnings Per Share (EPS)
- -0.06
Cash Flow
In the last 12 months, operating cash flow was -26.60M and capital expenditures -203,783, giving a free cash flow of -26.80M billion.
- Operating Cash Flow
- -26.60M
- Free Cash Flow
- -26.80M
- Free Cash Flow per Share
- -0.05
Dividends & Yields
Ondine Biomedical, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -23.61%
- Earnings Yield
- -35.92%
Stock Price Statistics
- Beta
- 0.33
- 52-Week Price Change
- -22.55%
- 50-Day Moving Average
- 10.09
- 200-Day Moving Average
- 11.88
- Relative Strength Index (RSI)
- 38.27
- Average Volume (3m)
- 711.10K
Important Dates
Ondine Biomedical, Inc. upcoming earnings date is May 20, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 30, 2026
- Next Earnings Date
- May 20, 2027
- Ex-Dividend Date
- ―
Financial Position
Ondine Biomedical, Inc. as a current ratio of 1.23, with Debt / Equity ratio of 11.85%
- Current Ratio
- 1.23
- Quick Ratio
- 1.06
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.35
- Interest Coverage Ratio
- -1427.14
Taxes
In the past 12 months, Ondine Biomedical, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Ondine Biomedical, Inc. EV to EBITDA ratio is -3.34, with an EV/FCF ratio of -4.05.
- EV to Sales
- 38.00
- EV to EBITDA
- -3.34
- EV to Free Cash Flow
- -4.05
- EV to Operating Cash Flow
- -4.08
Balance Sheet
Ondine Biomedical, Inc. has GBX 5.36M in cash and marketable securities with GBX 278.87K in debt, giving a net cash position of GBX 5.08M billion.
- Cash & Marketable Securities
- GBX 5.36M
- Total Debt
- GBX 278.87K
- Net Cash
- GBX 5.08M
- Net Cash Per Share
- GBX 0.01
- Tangible Book Value Per Share
- -GBX 0.01
Margins
Gross margin is 44.26%, with operating margin of -1158.92%, and net profit margin of -1150.26%.
- Gross Margin
- 44.26%
- Operating Margin
- -1158.92%
- Pretax Margin
- -1150.26%
- Net Profit Margin
- -1150.26%
- EBITDA Margin
- -1139.23%
- EBIT Margin
- -1158.92%
Analyst Forecast
The average price target for Ondine Biomedical, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 26.99%
- EPS Growth Forecast
- 4.36%
Scores
- Smart Score
- 6
- AI Score
- 44
